SCHEMBL6360966

SCHEMBL6360966

Cc1ccc(-c2ccccc2-c2nnnn2Cc2ccc([N+](=O)[O-])cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.48
AR P10275 2/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
P2RX7 Q99572 5/20 0.45
SLC6A2 P23975 2/20 0.45
SLC6A4 P31645 2/20 0.45
SLC6A3 Q01959 1/20 0.45
PKM P14618 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ALDH1A1 P00352 3/20 0.45
NPC1 O15118 1/20 0.45
MAPT P10636 1/20 0.45
RAB9A P51151 1/20 0.45
IDO1 P14902 1/20 0.44
TDO2 P48775 1/20 0.44
ACHE P22303 1/20 0.42
HSD17B10 Q99714 1/20 0.42
P2RY14 Q15391 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6360839 0.84 P2RX7 (0.62) LMNAKMT2AP2RX7ALDH1A1IDO1
SCHEMBL27514124 0.83 P2RX7 (0.62) LMNAARMEN1KMT2AP2RX7
SCHEMBL7286364 0.80 SMN1; SMN2 (0.68) LMNAMEN1KMT2APKMSMN1; SMN2
SCHEMBL6848952 0.80 NPC1 (0.53) LMNAMEN1KMT2AP2RX7PKM
SCHEMBL6355367 0.78 KMT2A (0.53) KMT2AP2RX7SLC6A2SLC6A4SLC6A3
SCHEMBL12173045 0.76 P2RX7 (0.59) LMNAMEN1KMT2AP2RX7ALDH1A1
SCHEMBL7284502 0.76 SMN1; SMN2 (0.62) LMNASLC6A2SLC6A4SLC6A3PKM
SCHEMBL16872261 0.75 P2RX7 (0.60) LMNAKMT2AP2RX7ALDH1A1HDAC6
SCHEMBL6361627 0.75 P2RX7 (0.60) LMNAKMT2AP2RX7ALDH1A1HDAC6
SCHEMBL6848845 0.75 P2RX7 (0.60) LMNAKMT2AP2RX7ALDH1A1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US claimed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP claimed
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US disclosed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists TFAM, CYP11B2, CYP11B1 LMNA 1197/4885AR 827/4885MEN1 3860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.